Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular progressive supranuclear palsy

J Winikates1, J Jankovic

  • 1Department of Neurology, Baylor College of Medicine, Houston, Texas.

Journal of Neural Transmission. Supplementum
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biliary Enterocytozoon bieneusi infection in a dog under immunomodulatory therapy.

The Journal of small animal practice·2023
Same author

Hyperkinetic movement disorders in congenital disorders of glycosylation.

European journal of neurology·2019
Same author

McLeod syndrome: Five new pedigrees with novel mutations.

Parkinsonism & related disorders·2019
Same author

Association between non-communicable disease multimorbidity and health care utilization in a middle-income country: population-based study.

Public health·2018
Same author

Treatment options for chorea.

Expert review of neurotherapeutics·2017
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017
Same journal

Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons.

Journal of neural transmission. Supplementum·2010
Same journal

A diet for dopaminergic neurons?

Journal of neural transmission. Supplementum·2010
Same journal

Immunization as treatment for Parkinson's disease.

Journal of neural transmission. Supplementum·2010
Same journal

Gene therapy for Parkinson's disease.

Journal of neural transmission. Supplementum·2010
Same journal

Stem cells and cell replacement therapy for Parkinson's disease.

Journal of neural transmission. Supplementum·2010
Same journal

Neurogenesis in substantia nigra of parkinsonian brains?

Journal of neural transmission. Supplementum·2010
See all related articles

Progressive supranuclear palsy (PSP) can stem from cerebrovascular disease, not just idiopathic causes. Vascular PSP often presents with asymmetric, lower-body symptoms, distinguishing it from the idiopathic form.

Area of Science:

  • Neurology
  • Neuroscience
  • Vascular Neurology

Background:

  • Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder of unknown etiology.
  • Idiopathic PSP typically presents with specific clinical and pathological characteristics.
  • Investigating potential causes beyond idiopathic origins is crucial for understanding PSP.

Observation:

  • This study reviewed 128 patients diagnosed with PSP to identify evidence of cerebrovascular disease.
  • A subset of patients (23.3%) met criteria for vascular PSP.
  • Clinical and neuroimaging features were compared between vascular and idiopathic PSP groups.

Findings:

  • Vascular PSP was associated with asymmetric and predominantly lower-body involvement (p < 0.05).
  • While corticospinal and pseudobulbar signs, gait issues, dementia, and incontinence were more frequent in the vascular group, these did not reach statistical significance.

Related Experiment Videos

  • The findings suggest cerebrovascular disease as a potential cause of PSP.
  • Implications:

    • Cerebrovascular disease should be considered in the differential diagnosis of PSP.
    • Vascular PSP may be distinguished by greater asymmetry, lower body symptoms, and specific neurological signs.
    • Identifying vascular causes could lead to targeted treatments and improved patient outcomes.